Entellus Medical Inc (NASDAQ:ENTL) has been assigned an average recommendation of “Hold” from the nine research firms that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $18.00.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 price target for the company in a report on Monday, October 9th. TheStreet raised Entellus Medical from a “d” rating to a “c-” rating in a research note on Thursday, December 14th. ValuEngine raised Entellus Medical from a “sell” rating to a “hold” rating in a research note on Thursday, December 7th. Canaccord Genuity restated a “hold” rating and issued a $17.00 price objective on shares of Entellus Medical in a report on Tuesday, October 17th. Finally, William Blair lowered Entellus Medical from an “outperform” rating to a “market perform” rating in a report on Friday, December 8th.
Entellus Medical (ENTL) opened at $23.99 on Tuesday. Entellus Medical has a 52-week low of $11.47 and a 52-week high of $25.58. The stock has a market capitalization of $611.12, a P/E ratio of -18.74 and a beta of -0.02. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.92 and a quick ratio of 1.71.
Several large investors have recently bought and sold shares of ENTL. Aisling Capital LLC bought a new position in shares of Entellus Medical in the 3rd quarter worth $9,759,000. Gabelli Funds LLC bought a new stake in shares of Entellus Medical in the fourth quarter valued at about $8,473,000. Paulson & CO. Inc. bought a new stake in shares of Entellus Medical in the second quarter valued at about $1,701,000. Archon Capital Management LLC increased its position in shares of Entellus Medical by 14.9% in the third quarter. Archon Capital Management LLC now owns 550,224 shares of the medical technology company’s stock valued at $10,157,000 after acquiring an additional 71,404 shares during the last quarter. Finally, Havens Advisors LLC acquired a new stake in shares of Entellus Medical in the fourth quarter valued at about $1,684,000. Institutional investors and hedge funds own 74.02% of the company’s stock.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.